scholarly journals Controlled Release of Therapeutics from Thermoresponsive Nanogels: A Thermal Magnetic Resonance Feasibility Study

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1380
Author(s):  
Yiyi Ji ◽  
Lukas Winter ◽  
Lucila Navarro ◽  
Min-Chi Ku ◽  
João S. Periquito ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Controlled Release ◽  
Magnetic Resonance ◽  
Release Kinetics ◽  
Temperature Response ◽  
Local Drug Delivery ◽  
Whole Body ◽  
Therapeutic Drug ◽  
Temperature Modulation ◽  
Thermoresponsive Polymers

Thermal magnetic resonance (ThermalMR) accommodates radio frequency (RF)-induced temperature modulation, thermometry, anatomic and functional imaging, and (nano)molecular probing in an integrated RF applicator. This study examines the feasibility of ThermalMR for the controlled release of a model therapeutics from thermoresponsive nanogels using a 7.0-tesla whole-body MR scanner en route to local drug-delivery-based anticancer treatments. The capacity of ThermalMR is demonstrated in a model system involving the release of fluorescein-labeled bovine serum albumin (BSA-FITC, a model therapeutic) from nanometer-scale polymeric networks. These networks contain thermoresponsive polymers that bestow environmental responsiveness to physiologically relevant changes in temperature. The release profile obtained for the reference data derived from a water bath setup used for temperature stimulation is in accordance with the release kinetics deduced from the ThermalMR setup. In conclusion, ThermalMR adds a thermal intervention dimension to an MRI device and provides an ideal testbed for the study of the temperature-induced release of drugs, magnetic resonance (MR) probes, and other agents from thermoresponsive carriers. Integrating diagnostic imaging, temperature intervention, and temperature response control, ThermalMR is conceptually appealing for the study of the role of temperature in biology and disease and for the pursuit of personalized therapeutic drug delivery approaches for better patient care.

scholarly journals SCIDOT-18. NANOTHERAPEUTICS FOR NEUROSURGICALLY-APPLIED DRUG DELIVERY

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi275-vi275
Author(s):  
Catherine Vasey ◽  
Vincenzo Taresco ◽  
Stuart Smith ◽  
Cameron Alexander ◽  
Ruman Rahman
Keyword(s):  
Drug Delivery ◽  
Ex Vivo ◽  
Drug Formulation ◽  
Local Drug Delivery ◽  
Resection Margins ◽  
Therapeutic Drug ◽  
Tumour Resection ◽  
Combination Drug ◽  
Drug Encapsulation ◽  
Drug Concentrations

Abstract Design and implementation of innovative local drug delivery systems (DDS) may overcome current limitations in GBM treatment, such as the lack of therapeutic drug concentrations reaching residual GBM cells following surgery. Here we describe a novel DDS which utilises a bespoke mechanically engineered spray device, designed for safe surgical use, to deliver a mucoadhesive hydrogel containing chemotherapeutic nanoparticles (NPs) into the tumour resection margins. The overall aim is to spray a NP and polymer solution onto the resection cavity and potentially increase penetration of anti-cancer drugs within the 2 cm reoccurrence zone beyond the infiltrative margin. The mucoadhesive gel of choice, pectin, is currently used in other in vivo applications; however we have repurposed this for the brain. Pectin is biocompatible with GBM and human astrocyte cells in vitro and showed neither toxicity nor inflammation for up to 2 weeks upon orthotopic brain injection. Pectin is biodegradable in artificial CSF and is capable of being sprayed from the engineered device. A panel of polymeric, oil-based and polymer-coated NPs have been developed and optimised to maximise drug encapsulation of etoposide and olaparib as proof-of-concept for combination drug delivery. Etoposide/olaparib was chosen due to cytotoxicity from 5 GBM cell lines, including primary lines isolated from the invasive tumour margin (Mean IC50 of 1.1 µM and 8.3 µM respectively). The optimal NP/drug formulation (based on drug encapsulation, spray capability and bio-adhesiveness) will ultimately be assessed for tolerability and efficacy using orthotopic allograft and xenograft high-grade glioma models, including measurement of penetration of drug/nanoparticle in ex vivo murine and porcine brain using novel hybrid time-of-flight/Orbitrap TM secondary ion mass spectrometer (orbiSIMS) technology.

scholarly journals EXTH-25. A MECHANICALLY-ENGINEERED SPRAY TO INCREASE BRAIN PENETRATION OF CHEMOTHERAPEUTIC NANOPARTICLES IN THE TREATMENT OF HIGH GRADE GLIOMAS

2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi87-vi87
Author(s):  
Phoebe McCrorie ◽  
Vincenzo Taresco ◽  
Alison Ritchie ◽  
Phillip Clarke ◽  
David Scurr ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Formulation ◽  
Local Drug Delivery ◽  
Resection Margins ◽  
Therapeutic Drug ◽  
Tumour Resection ◽  
High Grade ◽  
Combination Drug ◽  
Drug Encapsulation ◽  
Drug Concentrations

Abstract Design and implementation of innovative local drug delivery systems (DDS) may overcome current limitations in GBM treatment, such as the lack of therapeutic drug concentrations reaching residual GBM cells following surgery. Here we describe a novel DDS which utilises a bespoke mechanically engineered spray device, designed for safe surgical use, to deliver a mucoadhesive hydrogel containing chemotherapeutic nanoparticles (NPs) into the tumour resection margins. The overall aim is to spray a NP and polymer solution onto the resection cavity and potentially increase penetration of anti-cancer drugs within the 2 cm reoccurrence zone beyond the infiltrative margin. The mucoadhesive gel of choice, pectin, is currently used in other in vivo applications; however we have repurposed this for the brain. Pectin is biocompatible with GBM and human astrocyte cells in vitro and showed neither toxicity nor inflammation for up to 2 weeks upon orthotopic brain injection. Pectin is biodegradable in artificial CSF and is capable of being sprayed from the engineered device. A panel of polymeric, oil-based and polymer-coated NPs have been developed and optimised to maximise drug encapsulation of etoposide and olaparib as proof-of-concept for combination drug delivery. Etoposide/olaparib were chosen due to cytotoxicity from 5 GBM cell lines, including primary lines isolated from the invasive tumour margin (Mean IC50 of 1.1 µM and 8.3 µM respectively). The optimal NP/drug formulation (based on drug encapsulation, spray capability and bio-adhesiveness) will ultimately be assessed for tolerability and efficacy using orthotopic allograft and xenograft high-grade glioma models, including measurement of penetration of drug/nanoparticle in ex vivo murine and porcine brain using novel hybrid time-of-flight/Orbitrap TM secondary ion mass spectrometer (orbiSIMS) technology.

The role of ultrasound and magnetic resonance in local drug delivery

2008 ◽  
Vol 27 (2) ◽  
pp. 400-409 ◽  
Author(s):  
Roel Deckers ◽  
Claire Rome ◽  
Chrit T.W. Moonen
Keyword(s):  
Drug Delivery ◽  
Magnetic Resonance ◽  
Local Drug Delivery

scholarly journals Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines

2021 ◽  
Vol 12 ◽  
Author(s):  
Lu Han ◽  
Ke Peng ◽  
Li-Ying Qiu ◽  
Meng Li ◽  
Jing-Hua Ruan ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Controlled Release ◽  
Immune Responses ◽  
Cancer Vaccines ◽  
Drug Delivery Systems ◽  
Rational Design ◽  
Release Kinetics ◽  
Delivery Systems ◽  
Release Drug ◽  
Multiple Drugs

Cancer vaccines represent among the most promising strategies in the battle against cancers. However, the clinical efficacy of current cancer vaccines is largely limited by the lack of optimized delivery systems to generate strong and persistent antitumor immune responses. Moreover, most cancer vaccines require multiple injections to boost the immune responses, leading to poor patient compliance. Controlled-release drug delivery systems are able to address these issues by presenting drugs in a controlled spatiotemporal manner, which allows co-delivery of multiple drugs, reduction of dosing frequency and avoidance of significant systemic toxicities. In this review, we outline the recent progress in cancer vaccines including subunit vaccines, genetic vaccines, dendritic cell-based vaccines, tumor cell-based vaccines and in situ vaccines. Furthermore, we highlight the efforts and challenges of controlled or sustained release drug delivery systems (e.g., microparticles, scaffolds, injectable gels, and microneedles) in ameliorating the safety, effectiveness and operability of cancer vaccines. Finally, we briefly discuss the correlations of vaccine release kinetics and the immune responses to enlighten the rational design of the next-generation platforms for cancer therapy.

scholarly journals Encapsulation of Nicardipine Hydrochloride and Release from Biodegradable Poly(D,L-lactic-co-glycolic acid) Microparticles by Double Emulsion Process: Effect of Emulsion Stability and Different Parameters on Drug Entrapment

2017 ◽  
Vol 2017 ◽  
pp. 1-13 ◽  
Author(s):  
Nopparuj Soomherun ◽  
Narumol Kreua-ongarjnukool ◽  
Sorayouth Chumnanvej ◽  
Saowapa Thumsing
Keyword(s):  
Drug Delivery ◽  
Controlled Release ◽  
Glycolic Acid ◽  
Release Kinetics ◽  
Double Emulsion ◽  
Average Diameter ◽  
Optimal Processing ◽  
Alternative Drug ◽  
Biodegradable Poly

Poly(D,L-lactic-co-glycolic acid) (PLGA) is an important material used in drug delivery when controlled release is required. The purpose of this research is to design and characterize PLGA microparticles (PLGA MPs) implants for the controlled release of nicardipine hydrochloride (NCH) in vitro. This study used the water-in-oil-in-water (w1/o/w2) double emulsion and solvent diffusion/evaporation approach to prepare PLGA MPs. Optimal processing conditions were found, such as polymer content, surfactant type, stabilizer concentration, inner and outer aqueous phase volumes, and stirring speed. The PLGA MPs for use as nicardipine hydrochloride (NCH) loading and release had spherical morphology, and the average diameter was smaller than 5.20±0.25 μm. The release kinetics were modeled to elucidate the possible mechanism of drug release. In vitro release studies indicated that the NCH release rate is slow and continuous. PLGA MPs are an interesting alternative drug delivery system, especially for use with NCH for biomedical applications.

scholarly journals A mechanically-engineered spray to increase brain penetration of chemotherapeutic nanoparticles in the treatment of high-grade gliomas

2019 ◽  
Vol 21 (Supplement_4) ◽  
pp. iv1-iv1
Author(s):  
Phoebe McCrorie ◽  
Vincenco Taresco ◽  
Zeyuan Xu ◽  
Alison Ritchie ◽  
Phillip Clarke ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Formulation ◽  
Local Drug Delivery ◽  
Resection Margins ◽  
Therapeutic Drug ◽  
Tumour Resection ◽  
High Grade ◽  
Combination Drug ◽  
Drug Encapsulation ◽  
Drug Concentrations

Abstract Design and implementation of innovative local drug delivery systems (DDS) may overcome current limitations in GBM treatment, such as the lack of therapeutic drug concentrations reaching residual GBM cells following surgery. Here we describe a novel DDS which utilises a bespoke mechanically engineered spray device, designed for safe surgical use, to deliver a mucoadhesive hydrogel containing chemotherapeutic nanoparticles (NPs) into the tumour resection margins. The overall aim is to spray a NP and polymer solution onto the resection cavity and potentially increase penetration of anti-cancer drugs within the 2 cm reoccurrence zone beyond the infiltrative margin. The mucoadhesive gel of choice, pectin, is currently used in other in vivo applications; however we have repurposed this for the brain. Pectin is biocompatible with GBM and human astrocyte cells in vitro and showed neither toxicity nor inflammation for up to 2 weeks upon orthotopic brain injection. Pectin is biodegradable in artificial CSF and is capable of being sprayed from the engineered device. A panel of polymeric, oil-based and polymer-coated NPs have been developed and optimised to maximise drug encapsulation of etoposide and olaparib as proof-of-concept for combination drug delivery. Etoposide/olaparib was chosen due to cytotoxicity from 5 GBM cell lines, including primary lines isolated from the invasive tumour margin (Mean IC50 of 1.1 µM and 8.3 µM respectively). The optimal NP/drug formulation (based on drug encapsulation, spray capability and bio-adhesiveness) will ultimately be assessed for tolerability and efficacy using orthotopic allograft and xenograft high-grade glioma models.

scholarly journals Overview of implantable and injectable biomaterials in immunotherapy

2021 ◽  
Vol 16 (1) ◽  
pp. 195-201
Author(s):  
Prerana Prakash ◽  
Pushpa Agrawal ◽  
AH Manjunatha Reddy
Keyword(s):  
Drug Delivery ◽  
Immune Response ◽  
Side Effects ◽  
Drug Release ◽  
Cancer Vaccines ◽  
Release Kinetics ◽  
Local Drug Delivery ◽  
Systemic Immune Response ◽  
Immunomodulatory Agents ◽  
Target Side

Immunotherapy has shown promising applications in cancer treatment as it boosts the systemic immune response. Existing immunotherapy strategies have certain drawbacks which can be addressed by engineered biomaterials. In this review, we focused on advanced immunotherapy methods involving implantable and injectable biomaterials for the treatment of cancer. Engineered biomaterials as carriers for immunomodulatory agents aid in the local drug delivery, thus reducing the frequency of off-target side effects. Also, biomaterial-based cancer vaccines have the potential to target specific tissues by finely altering the physical properties of the drug to achieve desired drug release kinetics.

scholarly journals Formulation Development, Characterization and In-vitro Evaluation of Tamoxifen Loaded Liposomes

2020 ◽  
pp. 64-82
Author(s):  
Md. Mazed Hasan ◽  
Md. Hamiduzzaman ◽  
Ishrat Jahan ◽  
A. H. M. Nazmul Hasan ◽  
Md. Asaduzzaman
Keyword(s):  
Drug Delivery ◽  
Controlled Release ◽  
Side Effects ◽  
Cancer Treatment ◽  
Drug Delivery System ◽  
Delivery System ◽  
Ex Vivo ◽  
Release Kinetics ◽  
Formulation Development

Background: The study was aimed to prepare and evaluate tamoxifen loaded controlled release liposomes to reduce the side effects of tamoxifen during cancer treatment.  Methods: Different tamoxifen loaded liposomes were prepared by modified ether injection (MEIM) and thin film hydration method (TFHM) under prescribed conditions. The prepared liposomes were characterized by using optical microscopy, evaluating encapsulation efficiency, in-vitro and ex-vivo diffusion studies by using dialysis membrane and chicken intestinal sac respectively. Results: The data revealed that all of the liposomes were spherical in shape and stable under three physical conditions i.e. 4, 25 and 37 ± 2°C temperatures and 60 ±5% relative humidity. Additionally most of the liposomes followed zero order and class II release kinetics. It was also observed that with the increase of phospholipids and cholesterol, entrapment efficiency of liposome vesicles increased thus giving a controlled release drug delivery system but further increase reduced this efficiency at a certain level. Conclusion: The formulated control release liposomes might be a good drug delivery system for target oriented drug delivery with minimum side effects of tamoxifen during cancer treatment.

Sign in / Sign up

Export Citation Format

Share Document